US2015344883A1PendingUtilityA1

Methods and compositions involving mirna and mirna inhibitor molecules

63
Assignee: ASURAGEN INCPriority: Nov 12, 2004Filed: Jun 12, 2015Published: Dec 3, 2015
Est. expiryNov 12, 2024(expired)· nominal 20-yr term from priority
Inventors:David BrownLance FordAngie ChengRich JarvisMike ByromDmitriy OvcharenkoEric DevroeKevin Kelnar
A61P 43/00A61P 37/00A61P 9/10A61P 31/00A61P 25/28A61P 35/00A61P 31/06A61P 35/02A61P 25/00A61P 17/02A61P 17/00A61P 15/08A61P 11/00C12N 2310/14C12N 2310/3535C12N 2320/12A61N 5/10A61K 31/7088C12N 2310/321C12N 2310/3527C12Q 1/68C12N 2320/50A61K 31/7105C12N 2310/141C12N 2310/33C12N 15/113C12Q 1/6876C12N 2310/351C12Q 2600/178C12N 15/111C12N 2320/30C12N 2330/10A61K 31/713C12N 2310/322C12N 2310/344C12N 15/1136C12N 2310/312C12Q 2600/158C12N 2310/533A61K 9/127C12N 2310/35A61K 45/06
63
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present invention concerns methods and compositions for introducing miRNA activity or function into cells using synthetic nucleic acid molecules. Moreover, the present invention concerns methods and compositions for identifying miRNAs with specific cellular functions that are relevant to therapeutic, diagnostic, and prognostic applications wherein synthetic miRNAs and/or miRNA inhibitors are used in library screening assays.

Claims

exact text as granted — not AI-modified
1 . A method of treating hepatocellular carcinoma in an individual in need thereof, comprising administering to the individual a therapeutically-effective amount of miRNA inhibitor comprising a nucleic acid sequence that is at least 90% complementary to a miR-221 sequence. 
     
     
         2 . The method of  claim 1 , wherein the miRNA inhibitor comprises a sequence that is at least 90% complementary to 5-110 nucleotides of SEQ ID NO: 170. 
     
     
         3 . The method of  claim 1 , wherein the miRNA inhibitor comprises a sequence that is at least 90% complementary to at least 50 contiguous nucleotides of SEQ ID NO: 170. 
     
     
         4 . The method of  claim 1 , wherein the miRNA inhibitor comprises a sequence that is at least 90% complementary to at least 25 contiguous nucleotides of SEQ ID NO: 170. 
     
     
         5 . The method of  claim 1 , wherein the miRNA inhibitor comprises a sequence that is at least 90% complementary to at least 23 contiguous nucleotides of SEQ ID NO: 170. 
     
     
         6 . The method of  claim 1 , wherein the miRNA inhibitor comprises a sequence that is at least 90% complementary to at least 20 contiguous nucleotides of SEQ ID NO: 170. 
     
     
         7 . The method of  claim 1 , wherein the miRNA inhibitor comprises a sequence that is at least 90% complementary to at least 15 contiguous nucleotides of SEQ ID NO: 170. 
     
     
         8 . The method of  claim 1 , wherein the miRNA inhibitor comprises a sequence that is at least 90% complementary to at least 10 contiguous nucleotides of SEQ ID NO: 170. 
     
     
         9 . The method of  claim 1 , wherein the miRNA inhibitor comprises a sequence that is at least 90% complementary to at least 5 contiguous nucleotides of SEQ ID NO: 170. 
     
     
         10 . The method of  claim 1 , wherein the miRNA inhibitor comprises a sequence that is at least 90% complementary to nucleotides 65-87 of SEQ ID NO: 170. 
     
     
         11 . The method of  claim 1 , wherein the miRNA inhibitor comprises a sequence that is at least 90% complementary to a mature, naturally-occurring miR-221 sequence. 
     
     
         12 . The method of  claim 1 , wherein the miRNA inhibitor further comprises a pendant group conjugated to an end of the nucleic acid sequence. 
     
     
         13 . The method of  claim 1 , wherein the miRNA inhibitor is administered subcutaneously or intravenously.

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.